2014: Sebia launched the first milestone of its new CAPILLARYS 3 program: CAPILLARYS 3 TERA.
This new generation of capillary instruments offers all laboratories worldwide the necessary autonomy and flexibility to face their automation challenges of today and tomorrow.
1967: Sebia was founded and developed rapidly with the introduction of new innovative solutions for the clinical laboratories to answer their needs, both in term of new diagnostics tools, but also in term of automation throughput, quality and accuracy of the analysis.
1993: Sebia launched the HYDRASYS, one of the first systems able to semi-automatically carry out all types of electrophoresis on agarose gels. This opened the way for maximum standardization of all handling operations and considerably reduced the risk of errors.
2001: While expanding the menu of tests to be performed on agarose gel, the introduction of CAPILLARYS by Sebia was a real technological breakthrough. CAPILLARYS was a new generation capillary electrophoresis system adapted for clinical laboratories allowing complete automation of the technique. With its integrated bar code reading, it ensures full traceability of the samples along with high throughput analysis.
Since 2001: The company's development has been particularly strong in the field of capillary electrophoresis with the introduction of new tests including hemoglobin disorders, protein immunotyping, quantification of CDT (detection and monitoring for alcoholism) and HbA1c measurement for diabetes monitoring.
2007: MINICAP capillary electrophoresis system was launched. MINICAP is dedicated to smaller size laboratories that cannot access this innovative technology due to a lower volume of tests.
2008: HYDRASYS 2, the new self-contained complete system was launched. HYDRASYS 2 carries out all the different phases of electrophoresis testing, from sample application to the final reading. With HYDRASYS 2, Sebia offers an unrivalled range of electrophoresis solutions.
2010: Sebia launched the CAPILLARYS 2 FLEX PIERCING, building on the proven technology of the original CAPILLARYS instrument. CAPILLARYS 2 FLEX PIERCING provides additional test flexibility, and features cap piercing capability for improved workflow. This new instrument allows whole blood analysis from the primary tube for hemoglobin electrophoresis with no pre-analytical preparation, a true innovation for hemoglobinopathies testing.
2011: MINICAP FLEX PIERCING was launched, providing acess to small and medium laboratories to the whole blood cap piercing technology. Sebia also unveiled its CAPILLARYS Hb A1c kit, designed for the separation and measurement of HbA1c (glycated fraction of hemoglobin A0) in human blood by capillary electrophoresis. The Sebia CAPILLARYS Hb A1c method is NGSP certified and IFCC standardized for use with the Sebia CAPILLARYS 2 FLEX PIERCING instrument. It provides a high throughput method with clear-cut and precise results.
2012: The HbA1c test was also made available on MINICAP FLEX PIERCING.
The acknowledged analytical performances, as well as the added value of the HbA1c clear-cut and precise separation by electrophoresis, allowed Sebia to very rapidly become a significant player in the Diabetes market worldwide.
